Prosigna®/pam50 en la toma de decisiones clinicas en pacientes con cancer de mama

Previous Page

Next Page

Page Background

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline

Substitution in the NCIC.CTG MA.5 Randomized Trial

Premenopausal N+

(n=710)

CMFx6

CEFx6

Levine MN, et al. J Clin Oncol. 2005;23:5166;.